contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Stenocare er aktiv i sundhedsbranchen. Virksomheden har specialiseret sig i udviklingen af ​​medicinsk cannabis. Stenocare er en af ​​de første spillere, der er begyndt at sælge medicinske cannabisolier i Danmark. I fremtiden vil virksomheden også vende sig til andre europæiske markeder med sit produktsortiment. Stenocares har sit hovedkontor med beliggenhed i Randers.

Stenocare

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER: STENOThis information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation...

<div class="abstract">STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:&nbsp; STENOThis information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on October 14, 2024.STENOCARE A/S ("Stenocare" or the "Company") is updating its guidance from August 20 2024, based on actual market performance in Q3 2024 which has impacted the Company's 2024 guidance. The guidance of gross sales of between 6-8 mDKK is now expected to be 4.5 mDKK for 2024. The Company is exploring various financing opportunities to meet both its short-term and long-term capital needs.</div>Based on the Q3 actual market performance, the Company is updating guidance for 2024 with gross sales of 4.5 mDKK. Stenocare has been working to resolve certain unfavorable market dynamics concerning pricing and reimbursement principles on products that impacted the Danish market. This has been a primary reason for lower sales than anticipated, and during Q3 2024 this unfavorable situation has not been resolved as expected. The Q3 2024 gross sales are approx. 1.1 mDKK and during Q3 the Company had to accept returns of approx. 2 mDKK for products that are near expiry date that were initially delivered to meet expected demand.Stenocare has revised the logistical supply principles together with the local pharma distributors, to minimize future risk of product returns in the Danish market.Looking into Q4 2024, the Company is in the process of preparing delivery of the new and innovative Astrum 10-10 oil product for both Australia and Germany. This is an important milestone for driving sales growth - as Astrum 10-10 gives Stenocare a unique position compared to existing medical cannabis oils in the markets.Capitalization: The Company is considering a range of financing options to address its capital requirements in both the short and long term. Stenocare expects to shortly announce more details for this plan, that will enable the company to grow and leverage the market potential ahead.

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!